San Antonio Breast Cancer Symposium

Imlunestrant shows significant progression-free survival benefits in advanced breast cancer, offering a promising treatment option for patients.

New research reveals hormone replacement therapy may lower breast cancer risk in BRCA carriers, challenging existing medical guidelines on HRT use.

A safety analysis reveals that sacituzumab govitecan and pembrolizumab combination therapy shows manageable side effects in treating metastatic triple-negative breast cancer.

A novel ctDNA assay identifies high-risk triple-negative breast cancer patients post-surgery, highlighting its potential as a crucial prognostic tool.

New research shows less invasive surgical options for breast cancer staging are as effective as traditional methods, enhancing patient quality of life.

New research reveals that preoperative breast MRI does not enhance outcomes for early-stage breast cancer patients, challenging its routine use in treatment plans.

Sacituzumab govitecan enhances quality of life for untreated advanced TNBC patients, despite increased gastrointestinal toxicities compared to chemotherapy.

Subgroup analyses reveal T-DXd significantly improves invasive disease-free survival in early-stage HER2-positive breast cancer compared to T-DM1, regardless of HER2 expression.

Tucatinib enhances frontline maintenance therapy for HER2-positive metastatic breast cancer, significantly improving progression-free survival compared to placebo.

An innovative AI model enhances breast cancer recurrence predictions, outperforming traditional methods and offering tailored treatment insights for patients.

Patients in the DESTINY-Breast09 trial report improved quality of life with T-DXd plus pertuzumab, highlighting distinct side effect profiles compared to standard care.

Aromatase inhibitors enhance disease-free survival in HR+/HER2+ early breast cancer, outperforming SERMs without compromising overall survival, according to ALTTO trial findings.

Discover the most anticipated breast cancer abstracts at the 2025 San Antonio Symposium, featuring groundbreaking studies in HR+, HER2+, and TNBC.

Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and TNBC. Vote now!

A regimen using the PD-L1 inhibitor atezolizumab in the neoadjuvant and adjuvant settings did not improve outcomes in patients with triple-negative breast cancer.

The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.

A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.

An analysis of phase 3 trials found tamoxifen significantly reduced 15-year ipsilateral breast recurrence in patients with “good risk” DCIS treated without radiation therapy.

In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.

Hope S. Rugo, MD, FASCO, discusses how the combination of elacestrant and abemaciclib compares with other treatment options for patients with advanced breast cancer, whether estrogen receptor-positive or HER2-negative.

Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic breast cancer.

A study of 9,146 patients found no OS difference among first-line CDK4/6 inhibitor combinations for HR+/HER2- metastatic breast cancer, presented at SABCS 2024.

Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen receptor-positive/HER2-negative metastatic breast cancer treatment.

In the phase 2 SOLTI VALENTINE trial, patritumab deruxtecan with or without letrozole showed similar efficacy to multiagent chemotherapy in HR-positive, HER2-negative breast cancer with fewer severe adverse events.

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, according to 6-year data from the OlympiA trial.

SHR-A1811 showed promising antitumor activity and acceptable tolerability in patients with HER2-positive breast cancer, according to results of the phase 2 FASCINATE-N trial.

T-DXd improves progression-free survival vs physician’s choice, regardless of time to progression or endocrine resistance, in HR-positive, HER2-low/-ultralow metastatic breast cancer.

An exploratory analysis of the KEYNOTE-522 study presented at the 2024 San Antonio Breast Cancer Symposium highlights predictive biomarkers for improved triple-negative breast cancer outcomes.

Aditya Bardia, MD, MPH, FASCO, discusses how fam-trastuzumab deruxtecan-nxki compares with physician’s choice of chemotherapy in estrogen receptor-positive/HER2-low breast cancer.

Immediate surgery significantly lowered local recurrence rates in elderly patients with breast cancer compared with delayed surgery, according to a meta-analysis presented at SABCS 2024.